Dmitri Simberg, PhD, associate professor in the University of Colorado Skaggs School of Pharmacy, released a new study of the effectiveness of different types of fluorescent labels used to monitor the accumulation of liposomes in tumors. The study was published on July 1, 2021, in ACS Nano.
Thirty days of radiation treatments — five days a week, with Saturdays and Sundays off — are difficult for even the toughest of adults. But for a child, they’re even harder to bear. They involve fasting, waking up early, and lying in a dark room alone, without even your parents there for support.
But if during treatment you can take a trip to Agrabah to hang out with Aladdin, Jasmine, and the rest of the characters in Disney’s live-action version of “Aladdin,” it makes the sessions a lot easier to bear — not to mention it makes time go by a lot faster.
Thanks to a new innovation at the CU Cancer Center, patients like 5-year-old Piper Lardes are able to do just that — watch their favorite show or movie during their treatment to make the whole experience just a little easier. The technology, called Radflix, has a calming effect on parents as well.
Two University of Colorado Cancer Center researchers have received a five-year R01 Award for $497,893 per year from the National Institutes of Health (NIH) to study a potential new drug treatment for salivary gland cancer. The award is part of an inter-campus collaboration between Antonio Jimeno, MD, PhD, co-leader of the Developmental Therapeutics Program, and Tin Tin Su, PhD, co-leader of the Molecular and Cellular Oncology Program.
A team of University of Colorado School of Medicine researchers recently published a paper offering new insight into the role that oxygen deprivation, or hypoxia, plays in cancer development. CU Cancer Center member Joaquin Espinosa, PhD, is the senior researcher on the paper, which he hopes will help lead to more targeted treatments for cancer.
Sabrina L. Spencer, PhD, is a CU Boulder researcher and CU Cancer Center member. Spencer recently won the Damon Runyon-Rachleff Innovation Award and the Emerging Leader Award. She will use the grants to continue her research on drug resistance in cancer cells.
Camille Stewart's article about medical cannabis explains issues around the drug’s legality, makes recommendations for its use before and after surgery and pushes for research on its effects on postoperative patients.
Craig Jordan, PhD, has spent more than 20 years developing better treatments for acute myeloid leukemia (AML), a rapidly progressing cancer of the blood and bone marrow that can spread to other parts of the body, including the lymph nodes, liver, spleen and central nervous system.
After nearly four years of work, a group of researchers and clinicians from the University of Colorado (CU) published a paper this week in the Clinical Cancer Research that shares findings from research looking at how the composition of ovarian cancer tumors changes during chemotherapy and contributes to therapeutic response.
July 1, 2020 marked the start of another year of funding for the Colorado Cancer Screening Program (CCSP) for Patient Navigation but just like most things in 2020… it’s not just another year for a decade long program.
The international First-line Radiosurgery for Small-Cell Lung Cancer (FIRE-SCLC) analysis led by University of Colorado Cancer Center researchers and published today in JAMA Oncology shows no overall survival benefit from whole-brain radiation compared with radiosurgery in patients with small cell lung cancer.
Benjamin Brewer, PsyD, is a University of Colorado Cancer Center investigator and health psychologist at the UCHealth University of Colorado Hospital Bone Marrow Transplant Program. Here CU Cancer Center talks with Dr. Brewer about his patients’ new worries and about how our health system is adapting to meet the mental health needs of cancer patients during COVID-19.
University of Colorado Cancer Center group shows CPT1A may be necessary for ovarian cancer spread, chemo-resistance. Moves toward clinical trial of CPT1A inhibitor, etomoxir, against chemo-resistant ovarian cancer.
Chemotherapy has been so unsuccessful against DIPG that researchers have questioned whether chemotherapy drugs are even able to reach the cancer. University of Colorado Cancer Center study shows, "... medicine does reach DIPG tissue in good quantities that have the potential to be effective against the tumor," says lead researcher.
“Two independent sources with the same scientific finding make you think it’s true,” says Jean Mulcahy-Levy, MD, investigator at CU Cancer Center and associate professor in the CU School of Medicine Department of Pediatrics.
Of 1,881 patients under age 19 diagnosed with cancers of the brain and central nervous system between 2000 and 2015, 52 percent of White patients lived five years from diagnosis, whereas only 44 percent of African American patients and 45 percent of Hispanic patients reached a similar milestone.
University of Colorado Cancer Center study presented at the 2020 Gastrointestinal Cancers Symposium shows patients with locally advanced rectal cancer receiving lower-than-recommended doses of neoadjuvant chemotherapy in fact saw their tumors shrink more than patients receiving the full dose.
University of Colorado Cancer Center study shows healthy form of the leukemia-causing gene MLL may push pluripotent stem cells (which have proven difficult to use in human patients) to become durable hematopoietic stem cells (which are usable in patients, but have until now been impossible to make).
Due in part to advanced surgical techniques, more effective medicines, and a multidisciplinary approach to treating the disease, University of Colorado Cancer Center is able to operate on 30+ percent of pancreatic cancer patients, nearly double the national average.
University of Colorado Cancer Center study presented at the American Association for Cancer Research (AACR) Annual Meeting 2019 shows that the clinical-stage drug, tarloxotinib, is active against NRG1-fusion cancers, in addition to the HER2/EGFR cancers for which the drug was originally designed.
University of Colorado Cancer Center study published in the journal Oncogene shows that while estrogen doesn’t directly affect triple-negative breast cancer cells, it can affect surrounding brain cells in ways that promote cancer cell migration and invasiveness.
While overall rates of colorectal cancer are down, the rate of young people getting the disease is up 22 percent over two decades. International leaders meet in Colorado to set the research agenda to figure out why.
A University of Colorado Cancer Center study published today in the journal Cancer Cell shows that leukemia undercuts the ability of normal cells to consume glucose, thus leaving more glucose available to feed its own growth.
Results of phase 1 and phase 2 clinical trials of the drug entrectinib in ROS1-positive non-small cell lung cancer (NSCLC) presented on the press program of the International Association for the Study of Lung Cancer (IASLC) 19th World Conference on Lung Cancer show a response rate of 77.4 percent for 53 patients evaluable for response, with median duration of response of 24.6 months.
University of Colorado Cancer Center study shows that common laboratory tests used to determine ROS1 status may return false-negative results, meaning that some patients who could benefit from ROS1-directed therapy may be slipping through the cracks.
CU researchers mine data of 583 patient samples of advanced differentiated thyroid cancer and 196 anaplastic thyroid cancers, showing genetic alterations, and "high mutation burden" that is an FDA-approved marker for immunotherapy.